Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Quanterix Granted Breakthrough Device Designation From FDA For NfL Test For Multiple Sclerosis
Blood-based assay has the potential to serve the multiple sclerosis (MS) community in management of relapsing-remitting form of the disease
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker
What 4 Analyst Ratings Have To Say About Quanterix
Over the past 3 months, 4 analysts have published their opinion on Quanterix (NASDAQ:QTRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Goldman Sachs Maintains Neutral on Quanterix, Lowers Price Target to $35
Goldman Sachs maintains Quanterix (NASDAQ:QTRX) with a Neutral and lowers the price target from $40 to $35.
Quanterix Reports Received Funding From Alzheimer’s Drug Discovery Foundation, No Terms Disclosed
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has partnered with the Alzheimer’s Drug Discovery
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
Quanterix’s Return On Capital Employed Insights
Quanterix (NASDAQ:QTRX) brought in sales totaling $30.29 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 27.87%, resulting in a loss of $20.03 million.
Goldman Sachs Upgrades Quanterix to Neutral, Announces $40 Price Target
Goldman Sachs analyst Matthew Sykes upgrades Quanterix (NASDAQ:QTRX) from Sell to Neutral and announces $40 price target.